Sources Eli Lilly TRIUMPH-4 topline results (December 2025) Eli Lilly TRIUMPH-1 Phase 3 topline results, including 80-week and 104-week extension data (May 21, 2026) Eli Lilly
Metoclopramide (Reglan) accelerates stomach emptying, directly counteracting semaglutide's mechanismsome providers use it strategically in the first 4 weeks before reducing the GLP-1 dose
As a dual GIP/GLP-1 receptor agonist, tirzepatide works through additional pathways that some patients respond to more strongly
By week 52 (1 year), average total loss reaches 20 to 22 percent, or 40 to 44 pounds for someone starting at 200 pounds
10.1371/journal.pone.0259821 69 YumukV.TsigosC.FriedM.SchindlerK.BusettoL.MicicD.et al (2015)
This is especially valuable in a competitive and fast-growing market like Denver, where multiple industries present strong opportunities